Press release
View this email in your browser

Cytovation Announces Dosing of First Patient in its Phase I/II CICILIA Trial Investigating CyPep-1 in Patients with Solid Cancers

Press Release

Bergen, Norway, and Schiphol, the Netherlands (May 26, 2020) – Cytovation AS (“Cytovation”), a clinical-stage biotechnology company focused on developing CyPep-1, a next-generation lytic immunotherapy, is pleased to announce that the first patient has today been successfully dosed in its Phase I/II CICILIA clinical trial. The CICILIA trial will investigate CyPep-1 in patients with advanced solid cancers (ClinicalTrials.gov Identifier: NCT04260529).

The aim of the open-label, dose-escalation Phase I/II trial is to evaluate the safety, efficacy and pharmacokinetics of CyPep-1 given as intratumoral injection. Up to 21 patients with advanced (unresectable Stage III) or metastatic (Stage IV) solid tumor malignancies will be recruited. Two renowned clinical centers in.. Read more
About CATO SMS: CATO SMS is a full-service clinical and regulatory contract research organization (CRO), specializing in complex areas such as (immuno-)oncology, advanced therapeutics and orphan diseases. CATO SMS has a center of excellence solely dedicated to oncology. With over 320 dedicated professionals with offices and operations in over 25 countries around the globe, the company brings a powerful blend of capabilities focused on supporting small and mid-sized biotech, top-tier pharmaceutical companies and investigator groups with their innovative research. We offer regulatory consulting and oncology drug development affairs in addition to clinical trial management services, with offices strategically located in close proximity from the FDA and EMA.
Website Website
LinkedIn LinkedIn
Twitter Twitter
Copyright © 2020 SMS-oncology BV, All rights reserved.


Our mailing address is:
info@sms-oncology.com

unsubscribe from this list    update subscription preferences 
 






This email was sent to newsletter@newslettercollector.com
why did I get this?    unsubscribe from this list    update subscription preferences
SMS-oncology · Walaardt Sacréstraat 401-403 · Schiphol, 1117 BM · Netherlands

Email Marketing Powered by Mailchimp